Institute for Myeloma and Bone Cancer Research, 9201 Sunset Boulevard, Suite 300, West Hollywood, CA, 90069, USA.
UCLA-Olive View Medical Center in Sylmar, 14445 Olive View Drive, Sylmar, CA, 91342, USA.
Target Oncol. 2019 Oct;14(5):551-561. doi: 10.1007/s11523-019-00666-0.
Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes.
We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL.
Using an enzyme-linked immunosorbent assay (ELISA), we assessed plasma (p) levels of BCMA in 171 CLL patients and compared them with levels in healthy individuals.
pBCMA levels were significantly higher among patients with CLL than those from healthy donors (p < 0.0001). Among patients with aggressive disease, pBCMA was elevated compared with patients with indolent disease (p < 0.001). Those with an initial pBCMA level in the highest quartile had a shorter time to first treatment compared with CLL patients with pBCMA levels in the lowest three quartiles (p < 0.0001). Among those in the highest quartile (pBCMA > 110.9 ng/mL), overall survival was shorter than those in the lowest three quartiles (p = 0.0007). Finally, among those patients who underwent serial pBCMA testing, changes in these levels correlated with changes in their clinical status.
Together, our findings show that pBCMA is a promising new prognostic and predictive indicator for patients with CLL.
慢性淋巴细胞白血病（CLL）是一种晚期 B 细胞恶性肿瘤。在另一种晚期 B 细胞恶性肿瘤（多发性骨髓瘤）中，可溶 B 细胞成熟抗原（sBCMA）的水平升高，并可预测预后。
我们旨在评估 sBCMA 作为 CLL 患者的可能预后因素和监测工具。
我们使用酶联免疫吸附测定（ELISA）检测了 171 例 CLL 患者的血浆（p）BCMA 水平，并将其与健康个体的水平进行了比较。
与健康供体相比，CLL 患者的 pBCMA 水平显著升高（p<0.0001）。与惰性疾病患者相比，侵袭性疾病患者的 pBCMA 水平升高（p<0.001）。与 pBCMA 水平处于最低三个四分位数的 CLL 患者相比，初始 pBCMA 水平处于最高四分位数的患者首次接受治疗的时间更短（p<0.0001）。在最高四分位数（pBCMA>110.9ng/ml）中，总生存期比最低三个四分位数的患者更短（p=0.0007）。最后，在接受连续 pBCMA 检测的患者中，这些水平的变化与他们的临床状况的变化相关。
综上所述，我们的研究结果表明，pBCMA 是 CLL 患者有前途的新预后和预测指标。
